AstraZeneca plc Rating Reiterated by Galvan Research (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by Galvan Research in a research note issued on Wednesday, American Banking News.com reports. They currently have a GBX 4,200 ($69.85) price target on the stock. Galvan Research’s price target points to a potential upside of 2.45% from the stock’s previous close.
AstraZeneca plc (LON:AZN) traded down 0.49% during mid-day trading on Wednesday, hitting GBX 4075.00. 1,454,989 shares of the company’s stock traded hands. AstraZeneca plc has a 1-year low of GBX 2932.00 and a 1-year high of GBX 4100.00. The stock has a 50-day moving average of GBX 3879.65 and a 200-day moving average of GBX 3458.. The company’s market cap is £51.223 billion.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Thursday, February 20th. They now have a GBX 3,617 ($60.15) price target on the stock. Finally, analysts at Berenberg Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, February 13th. They now have a GBX 3,570 ($59.37) price target on the stock. Ten research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 3,536.16 ($58.81).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.